MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
14.29
+0.18
+1.28%
Pre Market: 13.40 -0.89 -6.23% 08:31 06/10 EDT
OPEN
14.47
PREV CLOSE
14.11
HIGH
14.68
LOW
14.02
VOLUME
13.24K
TURNOVER
0
52 WEEK HIGH
30.98
52 WEEK LOW
13.81
MARKET CAP
11.09B
P/E (TTM)
-8.9101
1D
5D
1M
3M
1Y
5Y
1D
Closing Bell Movers: Super Micro slips 5% after $7B equity offering
TipRanks · 13h ago
Summit Therapeutics files for $500M common stock offering; shares slide over 9%
Seeking Alpha · 16h ago
BUZZ-Summit Therapeutics falls on launching $500 mln stock offering
Reuters · 16h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 16h ago
Summit Therapeutics announces $500M common stock offering
TipRanks · 16h ago
Summit Therapeutics Launches $500M Public Stock Offering To Fund Ivonescimab Development
Benzinga · 16h ago
SUMMIT THERAPEUTICS - PROCEEDS TO FUND IVONESCIMAB R&D, WORKING CAPITAL, AND GENERAL CORPORATE PURPOSES
Reuters · 16h ago
Summit Therapeutics Files For Mixed Shelf Offering; Size Not Disclosed
Benzinga · 16h ago
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.